News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Daily News New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Yael L. Maxwell May 08, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News HFSA 2023 Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships Shelley Wood October 13, 2023
News Features Heart Failure Care Has a Pipeline Problem: What’s the Fix? Shelley Wood December 20, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Young People With Cardiac Conditions Rarely Die From Sex Michael O'Riordan January 18, 2022